Low pain intensity after opioid withdrawal as a first step of a comprehensive pain rehabilitation program predicts long-term nonuse of opioids in chronic noncancer pain

Clinical Journal of Pain

Volumn 29, Issue 9, 2013, Pages 760-769

  Krumova, Elena K ^a   Bennemann, Philipp ^a   Kindler, Doris ^a   Schwarzer, Andreas ^a   Zenz, Michael ^a   Maier, Christoph ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

chronic noncancer pain; long term follow up; opioid medication; opioid withdrawal

Indexed keywords

ANALGESIC AGENT; BUPRENORPHINE; CLONIDINE; DIPYRONE; FENTANYL; FLUPIRTINE; GABAPENTIN; HYDROMORPHONE; LORAZEPAM; METHADONE; MORPHINE; NALOXONE; OPIATE; OXYCODONE; PARECOXIBE; PETHIDINE; PREGABALIN; TILIDINE; TRAMADOL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CHRONIC NONCANCER PAIN; CHRONIC PAIN; CLINICAL DECISION MAKING; COGNITIVE THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HOSPITAL PATIENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MOOD; NUMERICAL RATING SCALE; OBSERVATIONAL STUDY; OPIOID WITHDRAWAL; PAIN ASSESSMENT; PAIN DISABILITY INDEX; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RELAPSE; SHORT FORM 36; TREATMENT DURATION; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

EID: 84881534772     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e31827c7cf6     Document Type: Article

References (59)

1. Maier C, Hildebrandt J, Klinger R, et al. Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain - results of a double-blind placebo-controlled trial (MONTAS). Pain. 2002; 97:223-233. (Pubitemid 34607218)
2. Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004; 112:372-380. (Pubitemid 39550738)
3. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010.
4. Sorgartz H, Reinecke H, on behalf of teh German Pain Society. L angzeitanwendung von Opioiden bei nicht tumorbedingten Schmerzen (LONTS). German National Guideline for long-term opioid use in non-cancer pain http://www.awmf.org/leitlinien/detail/ll/041-003.html. Accessed on the January 13, 2012.
5. National opioid use guideline group. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain, 2010. Available at: http://nationalpaincentre.mcmaster.ca/opioid/. Accessed January 13, 2012.
6. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10:113-130.
7. Chou R, Ballantyne JC, Fanciullo GJ, et al. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guideline. J Pain. 2009; 10:147-159.
8. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin sytematic review and meta-analysis of randomized controlled trials. JAMA. 2005; 293:3043-3052. (Pubitemid 40965075)
9. Furlan AD, Sadoval JA, Mailis-Gagnon A, et al. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006; 174:1589-1594. (Pubitemid 43829515)
10. Noble M, Tregear SJ, Treadwell JR, et al. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage. 2008; 35:214-228.
11. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain a review of the evidence. Clin J Pain. 2008; 24:469-478.
12. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003; 349:1943-1953. (Pubitemid 37409712)
13. Rosenblum A, Joseph H, Fong C, et al. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003; 289:2370-2378. (Pubitemid 37430169)
14. Stannard CF. Opioids for chronic pain: promise and pitfalls. Curr Opin Support Palliat Care. 2011; 5:150-157.
15. Joranson DE, Ryan KM, Gilson AM, et al. Trends in medical use and abuse of opioid analgesics. JAMA. 2000; 283:1710-1714. (Pubitemid 30196211)
16. Okie SA. Flood of opioids, a rising tide of deaths. N Engl J Med. 2010; 363:1981-1985.
17. Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J Pain. 2006; 7:225-235.
18. Bjørn AB, Jepsen P, Larsson HJ, et al. Hospitalizations for opioid poisoning: a nation-wide population-based study in Denmark, 1998-2004. Addiction. 2009; 104:104-108.
19. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006; 81:103-107. (Pubitemid 41821793)
20. Crane E, Novak S. Opiate-related drug misuse deaths in six states: 2003. New DAWN Rep. 2006; 19:1-4.
21. Cicero TJ, Wong G, Tian Y, et al. Co-morbidity and utilization of medical services by pain patients receiving opioid medications: data from an insurance claims database. Pain. 2009; 144:20-27.
22. Kahan M, Srivastava A, Wilson L, et al. Misuse of and dependence on opioids. Study of chronic pain patients. Can Fam Physician. 2006; 52:1081-1087. (Pubitemid 44553330)
23. Skellan D, Novak S, Ball JK. Emergency department visits involving nonmedical use of selected prescribtopn drugs. MMWR. 2010; 59:705-707.
24. Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010; 170:1979-1986.
25. Boswell MV, Shah RV, Everett CR, et al. Interventional techniques in the management of chronic spinal pain: evidencebased practice guidelines. Pain Physician. 2005; 8:1-47. (Pubitemid 40361184)
26. Boswell MV, Trescot AM, Datta S, et al. Interventional techniques: evidence-based practice guidelines in the management of chronic spinal pain. Pain Physician. 2007; 10:7-111. (Pubitemid 46290965)
27. Deer TR, Krames ES, Hassenbusch SJ, et al. Polyanalgesic Consensus Conference 2007: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel. Neuromodulation. 2007; 10:300-328. (Pubitemid 47481102)
28. Patel VB, Manchikanti L, Singh V, et al. Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain. Pain Physician. 2009; 12:345-360.
29. Smith HS, Deer TR, Staats PS, et al. Intrathecal drug delivery. Pain Physician. 2008; 11:89-104.
30. Maier C, Gockel HH, Gruhn K, et al. Increased risk of suicide under intrathecal ziconotide treatment? A warning. Pain. 2011; 152:235-237.
31. Ruan X. Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician. 2007; 10:357-365. (Pubitemid 46554001)
32. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006; 104: 570-587.
33. Mitra S. Opioid-induced hyperalgesia: pathophysiology and clinical implications. J Opioid Manag. 2008; 4:123-130.
34. Chu LF, Angst MS, Clark JD. Opioid-induced hyperalgesia in humans molecular mechanisms and clinical considerations. Clin J Pain. 2008; 24:479-496.
35. Lee M, Silverman S, Hansen H, et al. Comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011; 14: 145-161.
36. Angst MS, Koppert W, Pahl I, et al. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain. 2003; 106:49-57. (Pubitemid 37329613)
37. Koppert W, Dern SK, Sittl R, et al. A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. Anaesthesiology. 2001; 95:395-402. (Pubitemid 32720728)
38. Chu LF, Clark JD, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain. 2006; 7:43-48. (Pubitemid 43097262)
39. Wang H, Weinsheimer N, Akbar M, et al. Altered pain thresholds during and after opioid withdrawal in patients with chronic low back pain. Schmerz. 2010; 24:257-261.
40. Ralphs JA, de Williams ACC, Richardson PH, et al. Opiate reduction in chronic pain patients: a comparison of patientcontrolled reduction and staff controlled cocktail methods. Pain. 1994; 56:279-288. (Pubitemid 24087978)
41. Hooten MW, Townsend CO, Sletten CD, et al. Treatment outcomes after multidisciplinary pain rehabilitation with analgesic medication withdrawal for patients with fibromyalgia. Pain Med. 2007; 8:8-16. (Pubitemid 46128762)
42. Baron MJ, McDonald PW. Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Manag. 2006; 2:277-282.
43. Townsend CO, Kerkvliet JL, Bruce BK, et al. A longitudinal study of the efficacy of a comprehensive pain rehabilitation program with opioid withdrawal: comparison of treatment outcomes based on opioid use status at admission. Pain. 2008; 140:177-189.
44. Kidner CL, Mayer TG, Gatchel RJ. Higher opioid doses predict poorer functional outcome in patients with chronic disabling occupational musculoskeletal disorders. J Bone Joint Surg. 2009; 91:919-927.
45. Kalso E, Allan LG, Dellemijn PLI, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain. 2003; 7:381-386. (Pubitemid 37101777)
46. Anderson R, Saiers JH, Abram S, et al. Accuracy in equianalgesic dosing: conversion dilemmas. J Pain Symptom Manage. 2001; 21:397-406. (Pubitemid 32452140)
47. Pereira J, Lawlor P, Vigano A, et al. Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing. J Pain Symptom Manage. 2001; 22:672-687. (Pubitemid 32725810)
48. Gockel H, Maier C. QUAST computer-assisted tool (QUAST) for documentation and quality assurance in pain treatment. Schmerz. 2000; 14:401-415. (Pubitemid 32010796)
49. Nagel B, Gerbershagen HU, Lindena G, et al. Development and evaluation of the multidimensional German pain questionnaire. Schmerz. 2002; 16:263-270. (Pubitemid 36002013)
50. Geisser ME, Roth RS, Robinson ME. Assessing depression among person with chronic pain using the Center for Epidemiological Studies-Depression Scale and the Beck Depression Inventory: a comparative analysis. Clin J Pain. 1997; 13:163-170. (Pubitemid 27251111)
51. Dillmann U, Nilges P, Saile H, et al. Assessing disability in chronic pain patients. Schmerz. 1994; 8:100-110.
52. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain. 2002; 100:213-217. (Pubitemid 35449233)
53. Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36). 1. Conceptual framework and item selection. Med Care. 1992; 30:473-483.
54. Hooten MW, Townsend CO, Bruce BK, et al. The effects of smoking status on opioid tapering among patients with chronic pain. Anesth Analg. 2009; 108:308-315.
55. Amato L, Davoli M, Minozzi S, et al. Methadone at tapered doses for the management of opioid withdrawal (Review) . The Cochrane Database of Systematic Reviews. 2005; 3:Art. No.: CD003409.
56. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010; 17:1113-1188.
57. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010; 9:807-819.
58. Vowles KE, Ashworth J. Is opioid withdrawal necessary within comprehensive pain rehabilitation programs? Pain. 2011; 152:1948-1950.
59. Jamison RN, Ross EL, Michna E, et al. Substance misuse treatment for high-risk chronic pain patients on opioid therapy: a randomized trial. Pain. 2010; 150:390-400.